Haploidentical Stem Cell Transplant Coordination in China
Coordinating Access to Haploidentical HSCT Programmes in China
China pioneered haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through the Beijing Protocol — an approach that has since been adopted by transplant centres in multiple countries. For patients who cannot find a matched unrelated donor, or who cannot wait for a registry search, China's haematology centres offer a well-documented and accessible pathway.
We help with coordination, documentation, and logistics — not with clinical advice or treatment decisions.
ChinaMed Waypoint is a coordination service, not a medical provider. We help arrange appointments and logistics. All decisions about transplantation — including whether it is appropriate and which protocol to use — must be made with your own haematologist and clinical team.
China's Position in Haploidentical Transplantation
Haploidentical HSCT — using a half-matched family donor — was once considered a high-risk procedure of last resort. Over the past two decades, Chinese haematologists transformed it into a mainstream, evidence-based treatment pathway through systematic clinical innovation.
The Beijing Protocol, developed at Peking University People's Hospital under Professor Huang Xiaojun, introduced a combination approach to graft-versus-host disease (GvHD) prevention. Published multicentre studies have reported significantly improved outcomes compared with earlier approaches. Its results — published in Blood, The Lancet Haematology, and other peer-reviewed journals — have reported survival rates comparable to matched sibling donor transplants in a number of disease settings, including some high-risk presentations.
Today, Chinese centres account for a substantial proportion of all haploidentical transplants performed globally. That accumulated clinical experience — in both adult haematology and paediatric blood disease — represents a genuine medical resource that is accessible to international patients.
Why Haploidentical Transplant Matters for Many Patients
The following is general clinical context. Whether haplo-HSCT is appropriate in any individual case is a determination for the treating haematologist.
No Matched Donor? A Family Member Can Give
Many patients who need a stem cell transplant are unable to find a fully matched unrelated donor through international registries. Haploidentical transplant uses any available first-degree relative — a parent, child, or sibling — as the donor, with only a 50% HLA match required. This makes transplant possible for a broader group of patients.
Shorter Wait Time for High-Urgency Cases
Searching international donor registries for a fully matched unrelated donor can take months. For patients where disease progression makes a long search impractical, haploidentical transplant using an available family donor may allow the process to begin sooner. Clinical timing decisions are made by the treating haematologist.
Paediatric Blood Disease: A Core Strength
China's haematology centres have extensive experience treating children with leukaemia, aplastic anaemia, and complex inherited blood disorders using haploidentical HSCT. Paediatric haplo-HSCT has been performed at Chinese centres for over two decades and is supported by published outcome data from multicentre studies.
Outcomes Data Grounded in Evidence
The Beijing Protocol's outcomes have been assessed in multicentre studies with long-term follow-up data. For AML, ALL, aplastic anaemia, and other indications, published results have reported outcomes that support haploidentical transplant as a clinically evaluated option — including in contexts beyond donor-unavailability alone. Individual suitability is determined by the treating team.
What This Coordination Service Covers
This page is for patients and families who are exploring haploidentical HSCT as a treatment pathway and want to understand how to access it in China. We help with the coordination and logistics — not with clinical decision-making.
- Identifying appropriate haematology departments with established haplo-HSCT programmes
- Explaining what documentation is typically required for international patient pre-assessment
- Coordinating submission of medical records, cytogenetics, and treatment history to the hospital
- Facilitating bilingual communication between patient families and the transplant team
- Supporting visa applications, accommodation planning, and extended-stay logistics for patient and donor
- Coordinating multi-stage scheduling across pre-transplant evaluation, conditioning, transplant, and recovery
- Helping plan follow-up after discharge, including remote communication with the treating team
What the Process Typically Involves
Haploidentical HSCT is a complex, multi-phase medical process. The following is general context only — your clinical team will determine the specifics for your individual situation.
Case Review & Eligibility Assessment
The transplant team reviews full medical records — diagnosis, cytogenetics, prior treatment, current disease status, and performance score — to determine whether haploidentical HSCT is appropriate and which protocol to use. This stage can often be completed remotely, with physical assessment required at a later point.
Donor Selection & HLA Typing
A suitable family donor is identified and HLA-typed. In haploidentical transplant, the donor shares approximately 50% of the patient's HLA markers. The clinical team assesses which family donor — parent, child, or sibling — is most appropriate based on age, health, and compatibility factors.
Conditioning & Admission
The patient receives a conditioning regimen to prepare the bone marrow for the new cells. This requires a hospital admission that typically begins 7–10 days before transplant. The patient and donor both need to be present in China from this stage.
Transplant & Initial Recovery
The stem cell infusion is typically a brief procedure conducted by the transplant team. The critical period follows: the patient remains in a sterile environment — typically in a laminar airflow room — for several weeks while the new immune system engrafts and blood counts recover.
Extended Recovery & Follow-up
After discharge from the clean room, patients typically remain in China for an extended monitoring period before it is considered safe to travel home. The duration is determined by the treating team based on recovery progress. Follow-up continues remotely with the Chinese transplant team and with local doctors.
Who This Coordination Service Is Designed For
The following is general guidance only. Your haematologist should be the primary person advising on clinical suitability.
This Service May Be Relevant If You…
- Have a blood cancer or bone marrow disorder requiring stem cell transplantation
- Do not have a fully matched unrelated donor available through your national registry
- Have been told by your haematologist that haploidentical transplant is a potential option
- Have a family member available to serve as a donor (parent, child, or sibling)
- Are coordinating care for a child with leukaemia, aplastic anaemia, or a complex blood disease
- Need help understanding how to approach a Chinese transplant centre and what the process involves
This Service Does Not Replace…
- A clinical assessment by a qualified haematologist — transplant eligibility is a medical determination
- Your existing treatment team's oversight and ongoing clinical recommendations
- A second medical opinion, which we strongly encourage before major treatment decisions
- Direct engagement with the transplant team, which is required before any clinical commitment
- Legal, insurance, or financial advice related to treatment abroad
Want to Read the Clinical Background First?
Before exploring coordination options, many visitors find it helpful to read a clear, evidence-based explanation of what haploidentical transplant is, how the Beijing Protocol works, and what published outcome data shows.
How We Can Help
ChinaMed Waypoint is a medical travel coordination service. We do not provide medical assessments, diagnoses, or treatment recommendations. Our role is logistical and organisational.
If you are exploring haploidentical HSCT in China, we can assist with:
- Explaining the typical steps involved in accessing haploidentical HSCT at a Chinese hospital
- Helping you understand what documentation is usually required for international patient eligibility review
- Connecting you with appropriate haematology departments and transplant units
- Coordinating the preparation and submission of medical records and supporting documents
- Supporting bilingual communication between patient families and the transplant team
- Coordinating extended-stay logistics for patient and accompanying family member or donor
- Facilitating communication of follow-up protocols after discharge
A Note on Decision-Making
Haploidentical stem cell transplant is one of the most significant medical procedures a patient can undergo. For families navigating this decision — especially for children — the combination of clinical complexity, emotional weight, and geographic distance can feel overwhelming.
Our role is not to recommend treatment. It is to reduce the practical barriers that prevent families from even getting a clear picture of what is available and how to access it — so that the clinical conversation with a qualified haematologist can happen on a solid, informed basis.
If you are trying to understand whether China's transplant programmes are worth exploring for your situation, we are available for an initial conversation — without commitment and without pressure.
Medical Disclaimer
This page is provided for informational purposes only. ChinaMed Waypoint is not a medical provider and does not offer medical advice, diagnosis, or treatment recommendations. All decisions about whether to undergo haploidentical stem cell transplantation — and where — must be made in consultation with qualified healthcare professionals, including a specialist haematologist. Scheduling coordination does not substitute for clinical assessment. Stem cell transplantation carries significant risks; eligibility, donor suitability, conditioning protocol, and treatment planning are medical determinations that must be made by a qualified clinical team.
Related Services & Resources
Online MDT Consultation
Most families begin with a remote MDT case review — submitting existing records to a Chinese haematology team before any travel is planned.
CAR-T Cell Therapy Coordination
For blood cancer patients where CAR-T is the preferred next step rather than transplant — or where both options are being evaluated.
Beijing Protocol: Evidence & Outcomes
Published outcome data on haploidentical HSCT in China — what the evidence shows and which patients benefit most.
Exploring all cancer care options in China?
Our cancer care coordination overview covers the full range — MDT reviews, CAR-T, haploidentical transplant, and hospital navigation.
Ready to Discuss Your Situation?
If you or a family member is exploring haploidentical HSCT in China — whether for a blood cancer, aplastic anaemia, or a complex paediatric blood disease — our coordination team can explain what the process typically involves and how to begin an inquiry.
There is no commitment required for an initial conversation. We can help you understand what documentation to prepare and what to expect from the assessment process at a Chinese transplant centre.